In 2021, NETRF funded Paul Schaffer, PhD, of the University of British Columbia, for a pilot project entitled “Preclinical Toxicity and Therapy Study of 225Ac-crown-TATE.” The study’s outcomes were recently published in the journal Nuclear Medicine and Biology. This study highlights a promising advancement in treating somatostatin receptor-2 (SSTR2) positive neuroendocrine tumors using a novel … Continue reading Advancing NET Treatment: A New Molecule for More Effective Targeted Alpha Therapy